Routes ofadministration By mouth PubChem CID 24958200 UNII HMC2H89N35 | CAS Number 1038915-60-4 ChemSpider 24531930 Molar mass 320.394 g/mol | |
Legal status US: Investigational New Drug | ||
Results of engot ov16 nova phase iii trial of niraparib in platinum sensitive ovarian cancer
Niraparib (originally MK-4827) is an orally active small molecule PARP inhibitor being developed by Tesaro to treat ovarian cancer.
Contents
- Results of engot ov16 nova phase iii trial of niraparib in platinum sensitive ovarian cancer
- Next steps for niraparib for ovarian cancer following on from the engot ov16 nova trial
- Clinical trials
- References
It is an inhibitor of PARP1 and PARP2.
Niraparib was granted fast track designation and Tesaro submitted a new drug application in 2016.
Chemically, MK-4827 is C19H20N4O (ignoring a possible tosylate group).
A 2012 study found that PARP inhibitors exhibit cytotoxic effects not based solely on their enzymatic inhibition of PARP, but by their trapping of PARP on damaged DNA, and the strength of this trapping activity was ordered niraparib >> olaparib >> veliparib.
Next steps for niraparib for ovarian cancer following on from the engot ov16 nova trial
Clinical trials
It has undergone a phase III trial for ovarian cancer. It is reported that the primary endpoint (progression-free survival, PFS) was met. Patients with and without a BRCA mutation both showed longer PFS.
As of June 2016 seven clinical trials have been registered for MK-4827.